26.17

2.02% -0.54

Dyne Therapeutics Inc (DYN)

Overview News Price History Option Chain Financials Why DYN Down? Discussions Forecast

Dyne Therapeutics Inc stock is traded at $26.17, with a volume of 1.78M. It is down -2.02% in the last 24 hours and up +11.74% over the past month. Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

Previous Close:

$26.71

Open:

$26.84

24h Volume:

1.78M

Relative Volume:

0.85

Market Cap:

$4.89B

Revenue:

Net Income/Loss:

$-451.71M

P/E Ratio:

-8.112

EPS:

-3.2261

Net Cash Flow:

$-462.19M

1W Performance:

+0.00%

1M Performance:

+11.74%

6M Performance:

+63.56%

1Y Performance:

+125.22%

1-Day Range:

$26.11

$27.30

1-Week Range:

$25.25

$27.30

52-Week Range:

$11.63

$27.30

Dyne Therapeutics Inc Stock (DYN) Company Profile

Name

Dyne Therapeutics Inc

Sector

Healthcare (1075)

Industry

Biotechnology (600)

Phone

(781) 786-8230

Address

1560 TRAPELO ROAD, WALTHAM

Employee

258

Twitter

Next Earnings Date

2026-07-27

Latest SEC Filings

DYN's Discussions on Twitter

Compare DYN vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DYN Dyne Therapeutics Inc	26.17	4.99B	0	-451.71M	-462.19M	-3.2261
VRTX Vertex Pharmaceuticals Inc	525.73	134.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	797.99	82.06B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	876.00	54.10B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	205.26	44.06B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	359.05	40.64B	5.76B	514.49M	1.10B	4.4813

Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-10-25	Upgrade	Oppenheimer	Perform → Outperform
Oct-10-25	Downgrade	Oppenheimer	Outperform → Perform
Aug-25-25	Upgrade	Raymond James	Outperform → Strong Buy
Jun-24-25	Initiated	Bernstein	Mkt Perform
Jun-11-25	Resumed	Raymond James	Outperform
Jun-02-25	Resumed	Oppenheimer	Outperform
May-29-25	Initiated	Evercore ISI	Outperform
Mar-12-25	Initiated	BMO Capital Markets	Outperform
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Dec-13-24	Initiated	Robert W. Baird	Outperform
Nov-26-24	Initiated	RBC Capital Mkts	Outperform
Oct-24-24	Downgrade	JP Morgan	Overweight → Neutral
May-21-24	Reiterated	Chardan Capital Markets	Buy
Apr-30-24	Initiated	Morgan Stanley	Overweight
Feb-20-24	Initiated	H.C. Wainwright	Buy
Feb-27-23	Upgrade	Raymond James	Outperform → Strong Buy
Feb-15-23	Initiated	Oppenheimer	Outperform
Jan-26-23	Initiated	Guggenheim	Buy
Jul-20-22	Initiated	Chardan Capital Markets	Buy
Jul-12-22	Initiated	Raymond James	Outperform
Oct-12-20	Initiated	JP Morgan	Overweight
Oct-12-20	Initiated	Jefferies	Buy
Oct-12-20	Initiated	Piper Sandler	Overweight
Oct-12-20	Initiated	Stifel	Buy

View All

Dyne Therapeutics Inc Stock (DYN) Latest News

Aug 12, 2026

Dyne Therapeutics stock hits 52-week high at 27.19 USD - Investing.com

Aug 12, 2026

Dyne Therapeutics stock hits 52-week high at 27.19 USD By Investing.com - Investing.com Canada

Aug 12, 2026

Biotech Stocks At 52-Week HighsALMR +30% On Q2 Reports, DYN, CGEM, DXCM, CAH - RTTNews

Aug 12, 2026

Aug 11, 2026

FMR LLC Expands Dyne Therapeutics Stake: A Strategic Bet on Neur - GuruFocus

Aug 11, 2026

Dyne Therapeutics (NASDAQ:DYN) Hits New 52-Week HighHere's What Happened - MarketBeat

Aug 11, 2026

The Bull Case For Dyne Therapeutics (DYN) Could Change Following FDA Clearance Of DYNE-302 Trial - simplywall.st

Aug 11, 2026

Aug 09, 2026

Discipline and Rules-Based Execution in DYN Response - Stock Traders Daily

Aug 09, 2026

Dyne Therapeutics (DYN) Gets FDA Clearance With Valuation Questions Back In Focus - Sahm

Aug 09, 2026

Aug 08, 2026

Dimensional Fund Advisors LP Has $17.24 Million Holdings in Dyne Therapeutics, Inc. $DYN - MarketBeat

Aug 08, 2026

Aug 07, 2026